Bioprocess Development of a Human Monoclonal Antibody against MERS-CoV: Analytical and Preclinical Studies
. To ensure stability and facilitate rapid deployment in outbreak scenarios, a lyophilized formulation of KNIH-88 was developed, maintaining structural integrity and biological activity under long-term storage. Collectively, these findings support KNIH-88 as a promising therapeutic antibody for MERS-CoV, combining potent antiviral efficacy, structural stability, and a formulation suitable for stockpiling and emergency use in endemic regions.
Authors
- Dong‐Gyu Jo (ORCID: https://orcid.org/0000-0003-2271-1076)
- Jongsun Lim (ORCID: https://orcid.org/0000-0002-9182-5088)
- Kyung-Chang Kim
- Soya Park (ORCID: https://orcid.org/0000-0002-2149-4420)
- Byoung Kwon Park
- Hansaem Lee
- So-Young Lee
- Ickhyun Cho
- Joo-Yeon Lee
- Yungjun Jeong
- Hwanui Jung
- Sangwon Hong
- Chan Ki Park
- Jimin Seo
Institutions
- Korea National Institute of Health (KR)
- PROTO Manufacturing (Canada) (CA)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Biomolecules & Therapeutics
- Published
- 2026-06-30
- DOI
- https://doi.org/10.4062/biomolther.2026.001
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Korea National Institute of Health